Optimind Pharma provides legal psychedelic-enhanced psychotherapy using ketamine capsules in a controlled environment to treat mental health conditions such as depression and PTSD. Their evidence-based treatment programs combine psychedelic medicine with therapeutic integration, offering measurable improvements in mood and cognitive function for patients with treatment-resistant conditions.
Funding
$106.4K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many individuals suffering from treatment-resistant mental health conditions, such as depression, anxiety, and PTSD, find limited relief from traditional therapies. These conditions can significantly impair daily functioning and overall quality of life, creating a need for alternative and more effective treatment options.
Solution
Optimind Pharma offers psychedelic-enhanced psychotherapy using ketamine capsules in a controlled clinical setting. Their programs combine psychedelic medicine with therapeutic integration, aiming to improve mood, cognitive function, and overall well-being. The treatment process includes an initial consultation with a physician and clinical psychologist to determine suitability, followed by either monotherapy or assisted therapy sessions. Patients can expect positive effects, including antidepressant effects and reduced suicidal ideation, with long-term benefits dependent on commitment to the healing journey.
Target Audience
Optimind Pharma's treatment programs are designed for individuals suffering from treatment-resistant mental health conditions, including depression, generalized anxiety disorder, PTSD, and trauma.
Features
- Ketamine-enhanced psychotherapy administered in a safe, controlled environment
- Treatment programs designed based on scientific research and therapeutic practices
- Initial consultation with a physician and clinical psychologist to assess suitability
- Monotherapy and assisted therapy options available, tailored to individual needs
- Focus on therapeutic processing and integration to maximize treatment benefits
- Potential future access to psilocybin for microdosing through a partnership with Manitari Pharma